Tenofovir & Lamivudine & Dolutegravir Tab 300mg + 300mg + 50mg

Description

Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir Tablet

• Product Overview
Tenofovir Disoproxil Fumarate + Lamivudine + Dolutegravir Tablet is a fixed-dose combination (FDC) antiretroviral therapy used for the management of HIV-1 infection. This combination contains three active antiviral agents from different classes that work together to suppress viral replication and help maintain control of HIV infection.

The combination is widely used as a complete HIV treatment regimen under the supervision of a healthcare professional.

• Available Strength
– Tenofovir Disoproxil Fumarate – 300 mg
– Lamivudine – 300 mg
– Dolutegravir – 50 mg

• Therapeutic Category
Antiviral Agent / Combination Antiretroviral Therapy (ART)

• Indications
Tenofovir + Lamivudine + Dolutegravir Tablet is indicated for:
– HIV-1 Infection Management
– First-Line Antiretroviral Therapy
– Long-Term HIV Treatment Regimens
– Combination Therapy for Viral Suppression (as prescribed)

• Common Side Effects
Some patients may experience:
– Headache
– Nausea
– Diarrhea
– Fatigue
– Dizziness
– Sleep disturbances

• Serious Side Effects
Seek immediate medical attention if any of the following occur:
– Kidney function problems
– Reduced bone mineral density
– Severe liver problems
– Severe allergic reactions
– Lactic acidosis (rare)

• Precautions
– Use only under healthcare professional supervision.
– Regular monitoring of kidney function, liver function, and treatment response is recommended.
– Inform healthcare providers about all medicines being taken due to possible interactions.
– Do not stop therapy without medical advice.
– Store below 25°C, protected from moisture and direct sunlight.

• Technical Information

• Active Ingredients
– Tenofovir Disoproxil Fumarate – 300 mg
– Lamivudine – 300 mg
– Dolutegravir – 50 mg

• Mechanism of Action
– Tenofovir and Lamivudine inhibit viral reverse transcriptase, preventing HIV DNA formation.
– Dolutegravir inhibits HIV integrase enzyme, blocking viral DNA integration into host cells.

Together, they reduce HIV replication and help achieve viral suppression.

• Dosage Form
Film-Coated Tablet

• Route of Administration
Oral

• Shelf Life
24–36 Months (depending on packaging and regulatory requirements)

• Storage Conditions
Store below 25°C in a dry place, protected from moisture.

• Product Specifications
Product Name:- Tenofovir + Lamivudine + Dolutegravir Tablet
Generic Name:- TDF + 3TC + DTG
Strength:- 300 mg + 300 mg + 50 mg
Dosage Form:- Film-Coated Tablet
Category:- HIV / Antiretroviral Therapy
Packaging:- Alu-Alu Blister / Customized Export Packing
Pack Size:- As per requirement
Shelf Life:- 24–36 Months
Storage:- Below 25°C
Origin:- India

• Regulatory Status & Supply Information
– Manufactured in WHO-GMP compliant facilities.
– Available for international HIV care markets.
– Export documentation support available.
– Private Label Manufacturing available where permitted.
– Third-Party Manufacturing available.
– Customized export packaging available.
– Bulk supply available for HIV programs, distributors, hospitals, NGOs, and government tenders.

• Who Should Source This Product?
This product is ideal for:
– Pharmaceutical Importers
– HIV Medicine Distributors
– Government Healthcare Programs
– NGO Healthcare Projects
– Hospital Procurement Companies
– Tender Suppliers
– Antiviral Medicine Suppliers

• Why Source From Mediora Exports?
– Trusted Pharmaceutical Exporter from India
– WHO-GMP Manufacturing Partners
– Competitive International Pricing
– Wide Pharmaceutical Product Portfolio
– Reliable Global Supply Chain
– Flexible Packaging Options
– Complete Export Documentation Support

• Contact Details
Mediora Exports

📧 Email: info@medioraexports.com
📱 Phone/WhatsApp: +91 99047 64844